BioSeek Licenses Two Novel Anti-Inflammatory Peptides
News Nov 14, 2008
BioSeek, Inc. announces that it has exclusively licensed two novel anti-inflammatory peptides from Amylin Pharmaceuticals, Inc.
The two novel peptides were identified as candidates for development by BioSeek as a result of an ongoing joint research collaboration initiated between the two companies in 2007. These two peptides will be the basis for proprietary optimization and development programs at BioSeek for potential indications outside of Amylin’s core therapeutic focus.
Under the collaboration, BioSeek applied its BioMAP® human biology screening systems to evaluate the potential of 500 peptides in Amylin’s proprietary polypeptide hormone library, PHORMOL™, to treat a range of inflammatory conditions.
From that pool of 500 peptides, BioSeek was granted the right to select and license two of the peptides for its own preclinical portfolio. In exchange for milestone payments and royalties payable to Amylin, BioSeek has the right to optimize, develop and outlicense the two selected peptides. BioSeek is also eligible to receive royalties if Amylin develops or licenses an additional limited set of peptides for uses identified in the collaboration.
“Exercising this license for two promising peptides from Amylin significantly expands our internal pipeline of drug candidates and demonstrates the broad utility of our BioMAP platform of predictive human biology screens to enhance and accelerate drug discovery,” said Michael C. Venuti, Ph.D., Chief Executive Officer of BioSeek.
“By generating predictive preclinical human data on the pharmacological properties of Amylin’s PHORMOL library, the BioMAP platform provided insight into the potential utility of the peptides across multiple therapeutic areas. We advanced this project rapidly to achieve the goal of identifying two promising anti-inflammatory peptides for BioSeek.”
The selection of two of the most promising lead peptides was guided by identification of dose-responsive anti-inflammatory activity across a broad panel of BioMAP systems.
BioSeek’s immediate objective is to bring these two peptides forward quickly through preclinical studies for both sequence optimization and pharmaceutical property improvements, with the intention of nominating preclinical candidates for further efficacy, toxicology and safety assessment.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018